The Clinical Spectrum of Acquired Hypomagnesemia: From Etiology to Therapeutic Approaches.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or original data
PubMed 40868117 · doi:10.3390/biomedicines13081862
What was done
This narrative review synthesizes the etiology, pathophysiological mechanisms, clinical complications, and management strategies of acquired hypomagnesemia, with a focus on drug-induced causes (including diuretics, antibiotics, antineoplastic agents, and immunosuppressants).
What was found
No quantitative data or numerical outcomes are reported in the abstract. The authors descriptively report that acquired hypomagnesemia results from impaired intestinal absorption, renal wasting, or drug toxicity, leading to neuromuscular, cardiovascular, and metabolic consequences. Management strategies highlighted include magnesium supplementation alongside renal-sparing adjunctive therapies such as amiloride and SGLT2 inhibitors.
Why it matters
It provides clinicians with a consolidated overview of pharmacological causes of magnesium wasting and highlights potential therapeutic adjuncts to reduce renal losses in hospital and outpatient settings.
Limits
The abstract describes a non-systematic narrative review containing no original patient data, sample size metrics, statistical comparisons, or protocolized study selection criteria. Absolute risk estimates, drug-specific incidence rates, and comparative treatment efficacies are not reported.
Cited by
- contradicts Almost all prescription medications prescribed for cognitive issues deplete magnesium levels.